Target-effector Interaction in the Natural Killer Cell System. IV. Modulation by Cyclic Nucleotides
Overview
Affiliations
Dibutyryl cAMP (dB-cAMP) and the cAMP elevating agents, prostaglandin E1, theophylline, and histamine markedly suppressed NK cytolytic function in a dose- and rate-dependent manner. The inhibition was rapidly induced and persisted in the presence of the drugs. Separate pretreatment of targets and highly purified NK cells, isolated by a target binding and velocity sedimentation technique, revealed that PGE1 and dB-cAMP acted at the level of the effector cell in a short-term cytolytic assay. In contrast to the inhibitory effects of cAMP elevating agents, dB-cGMP and carbamylcholine caused a small but significant acceleration in the rate of lysis and could compete with inhibitory doses of dB-cAMP to reduce the level of suppression thereby suggesting that the cAMP-cGMP ratio might be important in NK-mediated lysis. Insulin had no effect on NK activity, whereas T cell-mediated cytolysis was augmented by insulin and cGMP if the effector cells were taken early after alloimmunization but not later. Neither cAMP- nor cGMP-elevating agents affected the frequency of NK-target cell conjugates. These results are compatible with the hypothesis that cyclic nucleotides may be involved in triggering the lytic event within NK cells.
The Immunomodulatory Effect of Alpha-Lipoic Acid in Autoimmune Diseases.
Liu W, Shi L, Li S Biomed Res Int. 2019; 2019:8086257.
PMID: 31016198 PMC: 6446120. DOI: 10.1155/2019/8086257.
Cytosolic PLA2 is required for CTL-mediated immunopathology of celiac disease via NKG2D and IL-15.
Tang F, Chen Z, Ciszewski C, Setty M, Solus J, Tretiakova M J Exp Med. 2009; 206(3):707-19.
PMID: 19237603 PMC: 2699120. DOI: 10.1084/jem.20071887.
The Bi-Directional Relationship between Periodontal Disease and Hyperlipidemia.
Fentoglu O, Bozkurt F Eur J Dent. 2009; 2(2):142-6.
PMID: 19212526 PMC: 2633171.
Lysis-sensitive targets stimulate an elevation of cAMP in human natural killer cells.
Whalen M, Green C Immunology. 1998; 93(3):415-20.
PMID: 9640254 PMC: 1364092. DOI: 10.1046/j.1365-2567.1998.00411.x.
Vaillier D, Daculsi R, Gualde N Cancer Immunol Immunother. 1995; 40(1):65-71.
PMID: 7828169 PMC: 11037750. DOI: 10.1007/BF01517237.